Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-07-31

Clinical Trial Update: Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention [Phase 2]

View source ↗

Summary

Phase 2 trial update for vismodegib in basal cell carcinomas has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vismodegib (Vismodegib)

Snippet

Sponsor: University of Arizona | Conditions: Basal Cell Carcinomas | Phase 2 | Status: TERMINATED | Results posted: 2019-07-31